Glembatumumab vedotin: Completed Phase IIb enrollment

Celldex completed enrollment in the open-label, U.S. Phase IIb EMERGE trial evaluating 1.88 mg/kg IV glembatumumab vedotin given on day 1 of each 21-day cycle vs. single agent chemotherapy of the inve...